DE69930872T8 - Antikörper gegen verkürzten vegf-d und deren verwendungen - Google Patents

Antikörper gegen verkürzten vegf-d und deren verwendungen Download PDF

Info

Publication number
DE69930872T8
DE69930872T8 DE69930872T DE69930872T DE69930872T8 DE 69930872 T8 DE69930872 T8 DE 69930872T8 DE 69930872 T DE69930872 T DE 69930872T DE 69930872 T DE69930872 T DE 69930872T DE 69930872 T8 DE69930872 T8 DE 69930872T8
Authority
DE
Germany
Prior art keywords
vegf
shortened
antibodies against
antibodies
vegfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE69930872T
Other languages
English (en)
Other versions
DE69930872D1 (de
DE69930872T2 (de
Inventor
Marc G. Ludwig Inst. for Cancer Res. ACHEN, (Level 6, Entrance 5), Parkville
Steven Alan Ludwig Inst. for Cancer Res. STACKER, (Level 6, Entrance 5), Parkville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of DE69930872D1 publication Critical patent/DE69930872D1/de
Publication of DE69930872T2 publication Critical patent/DE69930872T2/de
Application granted granted Critical
Publication of DE69930872T8 publication Critical patent/DE69930872T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
DE69930872T 1998-12-21 1999-12-21 Antikörper gegen verkürzten vegf-d und deren verwendungen Active DE69930872T8 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11325498P 1998-12-21 1998-12-21
US113254P 1998-12-21
US13455699P 1999-05-17 1999-05-17
US134556P 1999-05-17
PCT/US1999/031332 WO2000037025A2 (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof

Publications (3)

Publication Number Publication Date
DE69930872D1 DE69930872D1 (de) 2006-05-24
DE69930872T2 DE69930872T2 (de) 2006-11-30
DE69930872T8 true DE69930872T8 (de) 2007-05-03

Family

ID=26810852

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930872T Active DE69930872T8 (de) 1998-12-21 1999-12-21 Antikörper gegen verkürzten vegf-d und deren verwendungen

Country Status (13)

Country Link
US (3) US6383484B1 (de)
EP (1) EP1140175B1 (de)
JP (1) JP4632543B2 (de)
KR (1) KR20010081089A (de)
CN (1) CN1330555A (de)
AT (1) ATE322909T1 (de)
AU (2) AU770332B2 (de)
CA (1) CA2355896A1 (de)
DE (1) DE69930872T8 (de)
DK (1) DK1140175T3 (de)
ES (1) ES2259247T3 (de)
PT (1) PT1140175E (de)
WO (1) WO2000037025A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
ES2239338T5 (es) * 1995-09-29 2013-05-31 Vegenics Pty Ltd Genes regulados y sus usos
CA2263890C (en) * 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
US7045133B2 (en) * 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
DE60131146T2 (de) * 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
ATE284701T1 (de) * 2000-03-02 2005-01-15 Ludwig Inst Cancer Res Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
WO2002064097A2 (en) * 2001-02-12 2002-08-22 The Penn State Research Foundation Vegf-d expression in brain cancer
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
ATE470676T1 (de) * 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
IL159225A0 (en) 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20040242851A1 (en) * 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
CA2493572A1 (en) 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
EP1571160B1 (de) * 2002-11-12 2010-03-10 Mochida Pharmaceutical Co., Ltd. Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper
US7608684B2 (en) * 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
DE10256410B3 (de) * 2002-12-02 2004-03-11 Daimlerchrysler Ag Verfahren zum Energiemanagement von Klimaanlagen
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
JP2006517586A (ja) * 2003-02-04 2006-07-27 ラドウィグ インスティテュート フォー キャンサー リサーチ 幹細胞のｖｅｇｆ−ｂ及びｐｄｇｆ調節
US20050043235A1 (en) * 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
TWI428143B (zh) 2006-01-18 2014-03-01 Gen Hospital Corp 增加淋巴功能之方法
US7667880B2 (en) * 2006-02-10 2010-02-23 Adobe Systems, Incorporated Method and apparatus for previewing digital motion picture content
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
CN101245106B (zh) * 2007-12-04 2011-07-20 澳赛尔斯生物技术（上海）有限公司 抗vegf受体单克隆抗体及其制备方法和应用
US7811776B2 (en) * 2007-12-05 2010-10-12 University Of Cincinnati Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease
WO2009143584A1 (en) * 2008-05-30 2009-12-03 Vegenics Limited Treatment of pulmonary edema
CA2729303A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
NZ594481A (en) * 2009-02-06 2012-09-28 Pepscan Systems Bv Truncated cystine-knot proteins
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
DK3912643T3 (da) 2009-02-13 2022-10-17 Immunomedics Inc Immunokonjugater med en intracellulært-spaltelig binding
US20120093811A1 (en) * 2009-04-03 2012-04-19 Simmonds Jason W Anti-vegf-d antibodies
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
EP2538965B1 (de) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges
EP2704751B1 (de) 2011-05-02 2019-04-17 Immunomedics, Inc. Ultrafiltrationskonzentration ausgewählter allotypen-antikörper für kleinvolumige verabreichung
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
PT2900277T (pt) 2012-12-13 2022-05-25 Immunomedics Inc Doses de imunoconjugados de anticorpos e sn-38 para melhorar a eficácia e diminuir a toxicidade
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
WO2015006734A1 (en) 2013-07-12 2015-01-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
AU2015219495B2 (en) 2014-02-21 2019-11-21 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CN108794629A (zh) * 2018-06-28 2018-11-13 浙江众意生物科技有限公司 一种vegf-d单克隆抗体及试剂盒
JPWO2022239720A1 (de) 2021-05-10 2022-11-17

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
ES2242227T5 (es) * 1996-07-15 2011-12-09 Chugai Seiyaku Kabushiki Kaisha Nuevo factor de tipo vegf.
CA2263890C (en) * 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
AU5439998A (en) * 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor
NZ505011A (en) * 1997-12-24 2004-12-24 Ludwig Inst Cancer Res Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
US6342221B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF

Also Published As

Publication number Publication date
KR20010081089A (ko) 2001-08-25
EP1140175A2 (de) 2001-10-10
AU2004202080A1 (en) 2004-06-10
CA2355896A1 (en) 2000-06-29
JP4632543B2 (ja) 2011-02-16
WO2000037025A3 (en) 2000-11-16
CN1330555A (zh) 2002-01-09
ES2259247T3 (es) 2006-09-16
US6383484B1 (en) 2002-05-07
EP1140175A4 (de) 2003-03-05
US7097986B2 (en) 2006-08-29
DK1140175T3 (da) 2006-08-14
US20040141917A1 (en) 2004-07-22
DE69930872D1 (de) 2006-05-24
US6730489B1 (en) 2004-05-04
AU3343200A (en) 2000-07-12
PT1140175E (pt) 2006-06-30
WO2000037025A2 (en) 2000-06-29
ATE322909T1 (de) 2006-04-15
DE69930872T2 (de) 2006-11-30
AU770332B2 (en) 2004-02-19
EP1140175B1 (de) 2006-04-12
JP2002532113A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
DE69930872T8 (de) Antikörper gegen verkürzten vegf-d und deren verwendungen
DE69309472T2 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
DE69227456D1 (de) Nachweis von kollagenabbau -i(in vivo)
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
TR200003181T2 (tr) Gelişmiş çoğaltılabilirliğe sahip FAP alfa'ya özgü antikor
BR0306444A (pt) Uso de anticorpos anti-tnf(alfa) e outra droga
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
DE69841273D1 (de) Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
DE69738868D1 (de) Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
ATE136906T1 (de) Antikörperantagonisten gegen humanes interleukin- 4
BR8606615A (pt) Polipeptideos complementares a peptideos ou proteinas tendo uma sequencia de aminoacidos ou sequencia de codificacao de nucleotidios conhecida ao menos parcialmente e metodos de projeto dos mesmos
ATE477279T1 (de) Ganglioside-assozierte rekombinante antikörper und deren gebrauch fuer diagnose und therapien von tumoren
NO986088D0 (no) Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi
DE69834643D1 (de) Adipozyten-spezifische protein homologe
ATE70280T1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
WO1995011975A3 (en) Retroviral superantigens, superantigen peptides, and methods of use
DE69115917D1 (de) Humane gammainterferonantagonisten
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DK1095143T3 (da) Inhibitor til diagnosticering og behandling af patienter med hæmofili A
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: ACHEN, MARC G., LUDWIG INST. FOR CANCER RES., , AU

Inventor name: STACKER, STEVEN ALAN, LUDWIG INST. FOR CANCER , AU

8364 No opposition during term of opposition